Home Markets Q32 Bio: Oppenheimer slashes price target on mixed trial results

Q32 Bio: Oppenheimer slashes price target on mixed trial results

Dec 11, 2024 comments off

Original source: https://www.investing.com/news/stock-market-news/q32-bio-oppenheimer-slashes-price-target–on-mixed-trial-results-3765273

You May Also Like

AI data center projects boost US warehouse demand and rents, real estate company JLL says

SpaceX and Tesla’s Terafab targets 2028 for volume chip production, Musk says

Dow outperforms as Wall Street rises, healthcare stocks lead gains 

Elice shares plunge 28% on debut as investor doubts over AI trade deepen

Rubio kicks off India visit with trade deal, Russian oil on agenda

Software upgrades eat nearly a third of companies’ IT budgets, survey finds